Fundamental Analysis of JASPER THERAPEUTICS INC(NASDAQ:JSPR) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to JSPR. JSPR was compared to 565 industry peers in the Biotechnology industry. While JSPR has a great health rating, there are worries on its profitability. JSPR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year JSPR has reported negative net income.

JSPR had a negative operating cash flow in the past year.

JSPR had negative earnings in each of the past 5 years.

JSPR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

JSPR has a worse Return On Assets (-63.90%) than 62.10% of its industry peers.

JSPR has a Return On Equity (-75.92%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-63.9%
ROE	-75.92%
ROIC	N/A

ROA(3y)-59.52%

ROA(5y)-66.5%

ROE(3y)-76.99%

ROE(5y)-123.64%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JSPR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for JSPR has been increased compared to 1 year ago.

There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

JSPR has an Altman-Z score of 8.08. This indicates that JSPR is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 8.08, JSPR belongs to the top of the industry, outperforming 84.70% of the companies in the same industry.

There is no outstanding debt for JSPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	8.08

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 7.61 indicates that JSPR has no problem at all paying its short term obligations.

JSPR has a Current ratio of 7.61. This is in the better half of the industry: JSPR outperforms 71.17% of its industry peers.

A Quick Ratio of 7.61 indicates that JSPR has no problem at all paying its short term obligations.

JSPR has a Quick ratio of 7.61. This is in the better half of the industry: JSPR outperforms 71.17% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.61
Quick Ratio	7.61

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

JSPR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.89%, which is quite impressive.

EPS 1Y (TTM)42.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.5%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

JSPR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.11% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y24.88%

EPS Next 2Y12.35%

EPS Next 3Y6.54%

EPS Next 5Y-3.11%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

JSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year JSPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.35%

EPS Next 3Y6.54%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for JSPR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

JASPER THERAPEUTICS INC

NASDAQ:JSPR (12/24/2024, 8:23:40 PM)

After market: 21.5 -0.21 (-0.97%)

21.71

-0.41 (-1.85%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2024-11-07/bmo

Earnings (Next)N/A N/A

Inst Owners97.69%

Inst Owner Change1.79%

Ins Owners1.27%

Ins Owner Change0%

Market Cap325.65M

Analysts86.25

Price Target74.75 (244.31%)

Short Float %13.88%

Short Ratio7.35

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-0.4%

Min EPS beat(2)-13.47%

Max EPS beat(2)12.67%

EPS beat(4)3

Avg EPS beat(4)6.42%

Min EPS beat(4)-13.47%

Max EPS beat(4)17.57%

EPS beat(8)6

Avg EPS beat(8)3.98%

EPS beat(12)9

Avg EPS beat(12)0.6%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)2.32%

PT rev (3m)1.99%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-3.62%

EPS NY rev (1m)-2.91%

EPS NY rev (3m)-10.8%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.89
P/tB	3.89
EV/EBITDA	N/A

EPS(TTM)-4.74

EYN/A

EPS(NY)-4.57

Fwd EYN/A

FCF(TTM)-3.91

FCFYN/A

OCF(TTM)-3.86

OCFYN/A

SpS0

BVpS5.58

TBVpS5.58

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-63.9%
ROE	-75.92%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-59.52%

ROA(5y)-66.5%

ROE(3y)-76.99%

ROE(5y)-123.64%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	48.62%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.61
Quick Ratio	7.61
Altman-Z	8.08

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)242.4%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)42.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.5%

EPS Next Y24.88%

EPS Next 2Y12.35%

EPS Next 3Y6.54%

EPS Next 5Y-3.11%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-5.85%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-19.32%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-19.66%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-21.24%

OCF growth 3YN/A

OCF growth 5YN/A

JASPER THERAPEUTICS INC (JSPR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens